NYSE: VTRVentas Inc Stock
$63.86+0.14 (+0.22%)
Updated Jun 13, 2025
VTR Price
$63.86
Fair Value Price
N/A
Market Cap
$28.82B
52 Week Low
$49.34
52 Week High
$71.36
P/E
182.46x
P/B
2.51x
P/S
5.91x
PEG
1.46x
Dividend Yield
2.16%
Revenue
$5.08B
Earnings
$142.33M
Gross Margin
42.5%
Operating Margin
13.76%
Profit Margin
2.8%
Debt to Equity
1.24
Operating Cash Flow
$1B
Beta
0.7
Next Earnings
Jul 30, 2025
Ex-Dividend
Jun 30, 2025
Next Dividend
Jul 17, 2025
VTR Overview
Ventas Incorporated is a real estate investment trust (REIT) that owns and manages health care facilities in the U.S. and internationally.The company's portfolio of 1,200 properties includes nursing homes, medical office buildings, rehabilitation and acute care centres, special care centres, laboratories and research centres, and medical-surgical centres with a total value of $25B. The company was spun off from Vencor in 1998 and is headquartered in Chicago,IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VTR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Facility REIT
Industry Rating
C
VTR
Ranked#4 of 16
Ranked#4 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.57 | B | |
| $28.81 | C | |
| $16.69 | C |
Be the first to know about important VTR news, forecast changes, insider trades & much more!
VTR News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VTR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VTR ($63.86) is trading above its intrinsic value of $17.33, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VTR is poor value based on its earnings relative to its share price (182.46x), compared to the US market average (31.36x)
P/E vs Market Valuation
VTR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more VTR due diligence checks available for Premium users.
Valuation
VTR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
182.46x
Industry
78.92x
Market
31.36x
VTR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
VTR is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
VTR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.51x
Industry
2.23x
VTR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VTR price to earnings growth (PEG)
For valuing profitable companies with growth potential
VTR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
VTR's financial health
Profit margin
Revenue
$1.4B
Net Income
$46.9M
Profit Margin
3.5%
VTR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.0B
Liabilities
$14.2B
Debt to equity
1.24
VTR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$321.1M
Investing
-$883.7M
Financing
-$149.1M
VTR vs Healthcare Facility REIT Stocks
Ventas Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.